Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ustun Celalettin, Morgan Elizabeth, Moodie Erica E M, Pullarkat Sheeja, Yeung Cecilia, Broesby-Olsen Sigurd, Ohgami Robert, Kim Young, Sperr Wolfgang, Vestergaard Hanne, Chen Dong, Kluin Philip M, Dolan Michelle, Mrózek Krzysztof, Czuchlewski David, Horny Hans-Peter, George Tracy I, Kristensen Thomas Kielsgaard, Ku Nam K, Yi Cecilia Arana, Møller Michael Boe, Marcucci Guido, Baughn Linda, Schiefer Ana-Iris, Hilberink J R, Pullarkat Vinod, Shanley Ryan, Kohlschmidt Jessica, Coulombe Janie, Salhotra Amandeep, Soma Lori, Cho Christina, Linden Michael A, Akin Cem, Gotlib Jason, Hoermann Gregor, Hornick Jason, Nakamura Ryo, Deeg Joachim, Bloomfield Clara D, Weisdorf Daniel, Litzow Mark R, Valent Peter, Huls Gerwin, Perales Miguel-Angel, Borthakur Gautam
Аннотация
METHODS: Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).
RESULTS: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P < 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P < 0.0001).
CONCLUSIONS: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score).